BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros.

PubWeight™: 10.12‹?› | Rank: Top 0.1%

🔗 View Article (PMID 18408710)

Published in Nature on April 13, 2008

Authors

Charles G Mullighan1, Christopher B Miller, Ina Radtke, Letha A Phillips, James Dalton, Jing Ma, Deborah White, Timothy P Hughes, Michelle M Le Beau, Ching-Hon Pui, Mary V Relling, Sheila A Shurtleff, James R Downing

Author Affiliations

1: Department of Pathology, St Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.

Associated clinical trials:

Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia | NCT00137111

Articles citing this

(truncated to the top 100)

DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature (2008) 38.13

The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88

Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med (2009) 10.54

Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science (2008) 9.25

Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature (2010) 8.48

Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature (2011) 6.39

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med (2014) 5.37

JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2009) 4.98

Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. Nat Genet (2009) 4.47

Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell (2012) 4.41

Polycomb group proteins: navigators of lineage pathways led astray in cancer. Nat Rev Cancer (2009) 4.40

Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet (2009) 4.35

Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol (2011) 4.34

Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov (2009) 4.12

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia (2010) 4.09

CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature (2011) 3.72

Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat Genet (2009) 3.71

Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood (2010) 3.66

Acute lymphoblastic leukaemia. Lancet (2013) 3.44

The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet (2013) 3.43

Clinical implications of the cancer genome. J Clin Oncol (2010) 3.11

Making sense of cancer genomic data. Genes Dev (2011) 3.01

Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood (2012) 2.82

Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood (2008) 2.76

RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. Nat Genet (2014) 2.72

Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2009) 2.54

CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood (2011) 2.52

Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat Med (2010) 2.50

Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest (2010) 2.44

Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer (2012) 2.35

Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood (2009) 2.15

IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development. Cancer Cell (2011) 2.05

Characterization of KRAS rearrangements in metastatic prostate cancer. Cancer Discov (2011) 2.02

Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia. Nature (2015) 1.96

Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia. Proc Natl Acad Sci U S A (2009) 1.92

Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia. Blood (2008) 1.89

Selective regulation of lymphopoiesis and leukemogenesis by individual zinc fingers of Ikaros. Nat Immunol (2013) 1.88

A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nat Genet (2013) 1.87

Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function. J Exp Med (2009) 1.80

Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. Blood (2008) 1.79

Cell of origin strongly influences genetic selection in a mouse model of T-ALL. Blood (2011) 1.78

Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia. Nat Genet (2010) 1.68

A Critical Examination of the "Bad Luck" Explanation of Cancer Risk. Cancer Prev Res (Phila) (2015) 1.68

Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies. Blood (2011) 1.67

Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol (2010) 1.62

Challenging issues in pediatric oncology. Nat Rev Clin Oncol (2011) 1.56

Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL. Blood (2014) 1.53

Ikaros inhibits megakaryopoiesis through functional interaction with GATA-1 and NOTCH signaling. Blood (2013) 1.52

IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. Haematologica (2012) 1.50

An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer. Nat Biotechnol (2009) 1.47

Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project. Blood (2012) 1.47

Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood (2011) 1.46

Ikaros stability and pericentromeric localization are regulated by protein phosphatase 1. J Biol Chem (2009) 1.43

BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance. J Hematol Oncol (2011) 1.43

A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression. J Exp Med (2015) 1.42

Metabolic gatekeeper function of B-lymphoid transcription factors. Nature (2017) 1.40

Molecular genetics of B-precursor acute lymphoblastic leukemia. J Clin Invest (2012) 1.38

EVI1-rearranged acute myeloid leukemias are characterized by distinct molecular alterations. Blood (2014) 1.35

Failure of CDKN2A/B (INK4A/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL. Genes Dev (2008) 1.33

Function of Ikaros as a tumor suppressor in B cell acute lymphoblastic leukemia. Am J Blood Res (2013) 1.33

Challenging the axiom: does the occurrence of oncogenic mutations truly limit cancer development with age? Oncogene (2012) 1.29

Breakpoint-specific multiplex polymerase chain reaction allows the detection of IKZF1 intragenic deletions and minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia. Haematologica (2012) 1.28

Mechanisms of clonal evolution in childhood acute lymphoblastic leukemia. Nat Immunol (2015) 1.28

Pax5 loss imposes a reversible differentiation block in B-progenitor acute lymphoblastic leukemia. Genes Dev (2014) 1.26

Reprogramming of primary human Philadelphia chromosome-positive B cell acute lymphoblastic leukemia cells into nonleukemic macrophages. Proc Natl Acad Sci U S A (2015) 1.24

Genome-wide analysis of Ollier disease: Is it all in the genes? Orphanet J Rare Dis (2011) 1.24

The origin and nature of tightly clustered BTG1 deletions in precursor B-cell acute lymphoblastic leukemia support a model of multiclonal evolution. PLoS Genet (2012) 1.23

An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions. Leukemia (2013) 1.22

Integrated genetic and epigenetic analysis of childhood acute lymphoblastic leukemia. J Clin Invest (2013) 1.19

Genomic characterization of childhood acute lymphoblastic leukemia. Semin Hematol (2013) 1.19

Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine. Blood (2015) 1.19

Chromosomal Loop Domains Direct the Recombination of Antigen Receptor Genes. Cell (2015) 1.17

The TEL-AML1 leukemia fusion gene dysregulates the TGF-beta pathway in early B lineage progenitor cells. J Clin Invest (2009) 1.15

IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia. PLoS One (2012) 1.15

What is the relevance of Ikaros gene deletions as a prognostic marker in pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia? Haematologica (2013) 1.14

Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells. Blood (2013) 1.13

An allele of IKZF1 (Ikaros) conferring susceptibility to childhood acute lymphoblastic leukemia protects against type 1 diabetes. Diabetes (2011) 1.13

High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations. Blood (2012) 1.09

The prenatal origins of cancer. Nat Rev Cancer (2014) 1.09

Transcription factor networks in B-cell differentiation link development to acute lymphoid leukemia. Blood (2015) 1.08

MicroRNAs in B cell development and malignancy. J Hematol Oncol (2012) 1.08

Stochastic modeling indicates that aging and somatic evolution in the hematopoetic system are driven by non-cell-autonomous processes. Aging (Albany NY) (2014) 1.08

Developmental origins and impact of BCR-ABL1 fusion and IKZF1 deletions in monozygotic twins with Ph+ acute lymphoblastic leukemia. Blood (2011) 1.07

Immunologically silent cancer clone transmission from mother to offspring. Proc Natl Acad Sci U S A (2009) 1.07

Ikaros, CK2 kinase, and the road to leukemia. Mol Cell Biochem (2011) 1.06

The evolution of thymic lymphomas in p53 knockout mice. Genes Dev (2014) 1.04

dbCRID: a database of chromosomal rearrangements in human diseases. Nucleic Acids Res (2010) 1.04

Activation-induced cytidine deaminase accelerates clonal evolution in BCR-ABL1-driven B-cell lineage acute lymphoblastic leukemia. Cancer Res (2010) 1.04

Candidate gene association study in pediatric acute lymphoblastic leukemia evaluated by Bayesian network based Bayesian multilevel analysis of relevance. BMC Med Genomics (2012) 1.03

Global genomic characterization of acute lymphoblastic leukemia. Semin Hematol (2009) 1.02

Illegitimate V(D)J recombination involving nonantigen receptor loci in lymphoid malignancy. Genes Chromosomes Cancer (2012) 1.02

Novel agents and biomarkers for acute lymphoid leukemia. J Hematol Oncol (2013) 1.02

Ikaros and tumor suppression in acute lymphoblastic leukemia. Crit Rev Oncog (2011) 1.01

Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor. Clin Cancer Res (2010) 0.99

Toward an evolutionary model of cancer: Considering the mechanisms that govern the fate of somatic mutations. Proc Natl Acad Sci U S A (2015) 0.99

Molecular allelokaryotyping of T-cell prolymphocytic leukemia cells with high density single nucleotide polymorphism arrays identifies novel common genomic lesions and acquired uniparental disomy. Haematologica (2009) 0.99

Genes commonly deleted in childhood B-cell precursor acute lymphoblastic leukemia: association with cytogenetics and clinical features. Haematologica (2013) 0.99

Functional interactions between Lmo2, the Arf tumor suppressor, and Notch1 in murine T-cell malignancies. Blood (2011) 0.98

FoxO1 induces Ikaros splicing to promote immunoglobulin gene recombination. J Exp Med (2012) 0.97

Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia. Front Oncol (2014) 0.97

Articles by these authors

MicroRNA expression profiles classify human cancers. Nature (2005) 69.12

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood (2009) 23.52

Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87

Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature (2007) 17.68

Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell (2002) 11.83

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med (2010) 10.64

Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med (2009) 10.54

The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89

Large-scale sequence analysis of avian influenza isolates. Science (2006) 9.87

Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science (2008) 9.25

Revised international prognostic scoring system for myelodysplastic syndromes. Blood (2012) 8.12

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood (2013) 8.00

Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med (2009) 7.95

Acute lymphoblastic leukemia. N Engl J Med (2004) 7.83

Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet (2012) 7.61

Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med (2002) 7.32

Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell (2002) 6.64

Dynamics of chronic myeloid leukaemia. Nature (2005) 6.63

Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature (2011) 6.39

Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet (2009) 6.35

Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet (2011) 6.06

Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol (2006) 5.96

Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med (2004) 5.86

Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood (2009) 5.72

Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet (2002) 5.55

Subnuclear compartmentalization of immunoglobulin loci during lymphocyte development. Science (2002) 5.47

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med (2014) 5.37

CREST maps somatic structural variation in cancer genomes with base-pair resolution. Nat Methods (2011) 5.34

Radial glia cells are candidate stem cells of ependymoma. Cancer Cell (2005) 5.21

Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature (2011) 5.20

A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature (2012) 5.02

JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2009) 4.98

Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat Genet (2011) 4.93

Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science (2012) 4.92

Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol (2009) 4.89

Implementing genomic medicine in the clinic: the future is here. Genet Med (2013) 4.89

Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood (2002) 4.88

Novel mutations target distinct subgroups of medulloblastoma. Nature (2012) 4.82

Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood (2003) 4.54

Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1. Nat Genet (2004) 4.45

Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. Cell Stem Cell (2009) 4.43

Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell (2012) 4.41

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood (2006) 4.40

Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med (2011) 4.37

Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet (2009) 4.35

The tumor lysis syndrome. N Engl J Med (2011) 4.29

Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood (2004) 4.21

Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med (2004) 4.16

Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood (2003) 4.15

Hematopoietic stem cell quiescence promotes error-prone DNA repair and mutagenesis. Cell Stem Cell (2010) 4.11

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol (2011) 4.10

Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol (2010) 4.09

Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest (2007) 4.07

Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA (2004) 4.04